$AGIO Bullish after-hours 15% move on positive 8-K filing.
Shares have made a very positive move afterhours on good volume after the release of its 8-K Inc announcing that the global phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint. Tomorrow will be a very positive day so be ready, it could move very fast.
Analyst average Recommendation Overweight
9 BUY
3 HOLD
Analyst average price target $85
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Analyst average Recommendation Overweight
9 BUY
3 HOLD
Analyst average price target $85
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.